Eglen Medicine, a Long-term Leader in AI-driven Drug Discovery, Secures VB100 Award for the Fourth Time

May 11, 2025 06:21 CST Updated 06:21

Evergreen Therapeutics

Innovative Drug Developer

2025.5

Suzhou

VBEF

Evergreen Therapeutics Ranks on the 2025 VB100 Innovative Pharmaceuticals and Biologics List

Founder and Chairman Dr. Tao Du poses for a photo at the award ceremony.

On May 9, the 2025 VBEF Future Healthcare and Pharmaceutical Top 100 Exhibition, hosted by Vbdata, was grandly held at the Suzhou International Expo Center. During the conference, the "2025 Future Healthcare Top 100 List" was released.Following its inclusion in the main VB100 list for three consecutive years, Evergreen Therapeutics has once again been honored on the VB100 Innovative Pharmaceuticals and Biologics list for the fourth time this year., fully demonstrating its professional strength and leading position in the AI pharmaceuticals field.The Future Healthcare 100 Strong Selection is considered one of the authoritative evaluation systems in China's healthcare innovation field.The main list is open to non-listed companies in the medical and health field. Based on the VB100 value assessment model, the list goes through a process of independent application by enterprises, review by the VB100 evaluation committee, cross-review by supporting organizations, and final review by the expert committee. It selects the top 100 innovative companies in terms of valuation from four major fields (innovative devices and intelligent manufacturing / innovative pharmaceuticals and biologics / medical and health innovation services / medical and health industry chain services).After nine years of practice and exploration, the evaluation system for the "Future Healthcare 100 Strong Series Rankings and Awards" has become increasingly refined, gradually expanding into a global innovative healthcare ecosystem evaluation framework that encompasses multiple dimensions, including enterprises, investment institutions, medical organizations, and industrial parks., the annual selection event has also attracted extensive attention and coverage from numerous well-known media outlets, institutions, and government officials.

2025.5

Since its establishment, Evergreen Therapeutics has always been committed to the mission of "focusing on clinical needs and benefiting patients worldwide," driving technological innovation in AI-enabled clinical research and advancing the internationalization of its self-developed pipelines. The company continuously iterates and refines its proprietary AI-powered clinical development platform, efficiently progressing the R&D of its internal pipelines. With the support of AI technology, Evergreen Therapeutics has obtained IND approval for six pipeline candidates and filed over 50 patents, covering key pharmaceutical markets globally. In addition to its internal pipeline development, Evergreen Therapeutics leverages its self-developed AI technologies and the team’s expertise in international pharmaceutical clinical trials and regulatory affairs to provide customized services for new drug global development. These include disease model analysis, combination therapy optimization, gap analysis in clinical development, Target Product Profile (TPP) design, orphan drug development strategies, optimal regulatory submission pathways, and overseas technology transfer consulting. To date, Evergreen Therapeutics has successfully helped multiple pharmaceutical companies obtain U.S. clinical trial approvals, earning a strong reputation within the industry.

The fourth VB100 award is a full affirmation of Evergreen Therapeutics' years of dedication to the innovative drug field, as well as high recognition and encouragement from the industry. In the future, Evergreen Therapeutics will continue to focus on the strategic core of "AI clinical technology + international development of innovative drugs," further deepen the application of AI technology in clinical development, and enhance the R&D efficiency and success rate of its proprietary pipeline drugs. Meanwhile, in the face of a complex international environment, the company will more firmly pursue a path that combines independent research and development with international cooperation. Relying on a global R&D network, it will continue to expand into international markets, assist more Chinese pharmaceutical companies in going global, and provide patients with precise and diversified treatment options.